MOMA Therapeutics has appointed Dr. Peter Hammerman as chief scientific officer, where he’ll lead the company’s initiatives in precision medicine. Hammerman comes from a background in cancer biology and previously served as global head of oncology translational research at Novartis Institute of Biomedical Research.